Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have chosen to take part voluntarily and have signed a consent form
• People aged 18 to 75 years old, of any gender
• People who have been diagnosed with stomach cancer (adenocarcinoma) or cancer at the junction of the stomach and food pipe, confirmed by a tissue sample test
• People whose cancer has been staged as Stage II–III (specifically T3–4a, any N, M0) according to standard cancer staging guidelines (confirm with trial site)
• People whose cancer has been assessed by doctors as able to be removed by surgery
• People who have at least one measurable tumour or affected lymph node that meets specific size requirements on a CT scan
• People who have not yet received any treatment for their cancer
• People with a good general physical activity level, rated 0 or 1 on a standard scale used by doctors (confirm with trial site)
• People whose major organs (such as liver, kidneys, and heart) are functioning well
• People without an active hepatitis B virus infection
• Women who could become pregnant must have had a negative blood pregnancy test within 3 days before joining, and must agree to use a reliable method of contraception during the trial and for 6 months after treatment ends
• Men must either have had a surgical sterilisation procedure or agree to use a reliable method of contraception during the trial and for 3 months after treatment ends

Who may not be able to join:

• People who are pregnant or breastfeeding
• People who have previously received any cancer treatment, including chemotherapy, radiotherapy, targeted therapy, or immunotherapy
• People who have had another type of cancer in the past 5 years (some exceptions may apply for certain less serious skin cancers, early-stage bladder cancer, cervical cancer in situ, or breast cancer — confirm with trial site)
• People who have uncontrolled fluid build-up around the lungs, heart, or in the abdomen
• People whose cancer has been assessed as unable to be surgically removed, or has spread to distant parts of the body
• People who have had serious heart conditions such as significant coronary artery disease, moderate-to-severe heart failure, uncontrolled irregular heartbeat, or a heart attack within the 12 months before joining
• People who have a blockage or bleeding in the upper digestive tract, or have significant problems with digestion or nutrient absorption
• People who have had a hole (perforation) in their digestive tract within the 6 months before joining
• People with a severe uncontrolled infection, other serious uncontrolled illness, or moderate to severe kidney problems
• People with poorly controlled heart conditions, including certain levels of heart failure, unstable chest pain (angina), a heart attack within the past year, significant irregular heart rhythms requiring treatment, or abnormal heart electrical readings above certain thresholds (confirm with trial site)
• People who are known to be allergic to any of the drugs used in this trial
• People who have used immune-suppressing medications within 4 weeks before the first dose (with some exceptions for low-dose or topical steroids — confirm with trial site)
• People who have had an organ transplant or bone marrow/stem cell transplant from a donor
• People with current or past significant lung inflammation or scarring conditions (such as interstitial lung disease, pulmonary fibrosis, or active tuberculosis), or who show signs of active lung inflammation on a screening CT scan
• People with an active autoimmune disease, or a history of autoimmune disease that could come back (some milder autoimmune conditions may still be eligible — confirm with trial site)
• People who have used immune-suppressing or high-dose steroid medications within 14 days before starting the trial
• People who have had a serious infection within 4 weeks before starting the trial, or who have been taking antibiotic treatment orally or by injection within the 2 weeks before starting (people taking antibiotics as a preventive measure may still be eligible — confirm with trial site)
• People with a known condition that weakens the immune system, such as HIV infection
• People who have received a live vaccine within 4 weeks before the first dose, or who plan to receive one during the trial
• People who have previously been treated with anti-PD-1 or anti-PD-L1 immunotherapy
• People who have had palliative radiotherapy to non-target areas and have not fully recovered from its side effects at least 2 weeks before starting the trial
• People who have taken part in another experimental drug trial within 28 days before starting this trial
• People who, in the opinion of the trial doctor, have other circumstances that could affect the trial results or their safety, such as significant alcohol use, drug misuse, serious mental health conditions, major abnormal test results, or significant personal or social circumstances

Important: Always verify eligibility with the trial site directly before applying.